Caribou Biosciences, Inc. License Agreements
8 Contracts & Agreements
- Amendment No. 3 to the Exclusive License Agreement, dated April 16, 2021, by and among the Registrant, The Regents of the University of California, and the University of Vienna (Filed With SEC on July 1, 2021)
- Amendment No. 2 to the Exclusive License Agreement, dated April 17, 2013, by and among the Registrant, The Regents of the University of California, and the University of Vienna (Filed With SEC on July 1, 2021)
- Amendment No. 1 to the Exclusive License Agreement, dated April 16, 2013, by and among the Registrant, The Regents of the University of California, and the University of Vienna (Filed With SEC on July 1, 2021)
- Exclusive License Agreement dated as of April 16, 2013, by and among the Registrant, The Regents of the University of California, and the University of Vienna (Filed With SEC on July 1, 2021)
- Addendum to License Agreement, dated as of February 2, 2016, by and between the Registrant and Intellia Therapeutics, Inc. as successor in interest to Intellia, LLC (Filed With SEC on July 1, 2021)
- Amendment No. 1 to the License Agreement, dated February 2, 2016, by and between the Registrant and Intellia Therapeutics, Inc. as successor in interest to Intellia, LLC (Filed With SEC on July 1, 2021)
- License Agreement dated as of July 16, 2014, by and between the Registrant and Intellia, LLC (Filed With SEC on July 1, 2021)
- Exclusive License Agreement dated as of November 13, 2020, by and between the Registrant and Memorial Sloan Kettering Cancer Center (Filed With SEC on July 1, 2021)
